Nanobodies binding TROP2 and uses thereof
AssigneeBiosion Inc.
InventorsMingjiu Chen, Mark Zhiqing Ma
Life of this patent
Estimating the term…
Abstract
A heavy chain only antibody that specifically binds human TROP2, or an antigen-binding portion thereof is provided. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. Further provided are an immunoconjugate and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an anti-TROP2 antibody or the antigen-binding portion thereof.
Claims19
A heavy chain only antibody, or an antigen-binding portion thereof, capable of binding to TROP2, comprising a variable region comprising a CDR1 region, a CDR2 region and a CDR3 region, wherein the CDR1 region, the CDR2 region and the CDR3 region comprise amino acid sequences set forth in
- (1) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are D, G, D and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are D and G, respectively;
- (2) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are D, G, D and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are E and G, respectively;
- (3) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are D, G, D and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are D and A, respectively;
- (4) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are D, G, D and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are I and G, respectively;
- (5) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are E, G, D and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are E and G, respectively;
- (6) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th 12th and 13th amino acid residues in SEQ ID NO:
- 2 are D, A, D and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are E and G, respectively;
- (7) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are E, G, D and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are D and A, respectively;
- (8) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are D, A, D and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are D and A, respectively;
- (9) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th 12th and 13th amino acid residues in SEQ ID NO:
- 2 are E, G, E and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are E and G, respectively;
- (10) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are D, A, E and S, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are E and G, respectively;
- (11) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are E, G, D and T, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are D and A, respectively;
- or
- (12) SEQ ID NOs:
- 1, 2 and 3, respectively, wherein 5th, 6th, 12th and 13th amino acid residues in SEQ ID NO:
- 2 are D, A, D and T, respectively, and 10th and 11th amino acid residues in SEQ ID NO:
- 3 are D and A, respectively.
A heavy chain only antibody, or an antigen-binding portion thereof, capable of binding to TROP2, comprising a variable region that comprises the amino acid sequence set forth in SEQ ID NOs:
- 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13,
- wherein 11th, 13th, 107th, 108th and 124th amino acid residues in SEQ ID NO:
- 4 are S, Q, D, G and P, respectively;
- S, Q, E, G and P, respectively;
- S, Q, D, A and P, respectively;
- S, Q, I, G and P, respectively;
- or T, G, D, G and L, respectively,
- wherein 54th, 55th and 61st amino acid residues in SEQ ID NO:
- 5 are E, G and D, respectively;
- D, A and D, respectively;
- E, G and E, respectively;
- or D, A and E, respectively,
- wherein 54th, 55th and 62nd amino acid residues in SEQ ID NO:
- 6 are E, G and S, respectively;
- D, A and S, respectively;
- E, G and T, respectively;
- or D, A and T, respectively,
- wherein 27th, 29th, 71st and 97th amino acid residues in SEQ ID NO:
- 8 are F, Y, K and A, respectively;
- L, F, K and A, respectively;
- L, Y, R and A, respectively;
- L, Y, K and R, respectively;
- or L, Y, K and A, respectively,
- wherein 27th, 29th, 71st and 97th amino acid residues in SEQ ID NO:
- 9 are F, Y, K and A, respectively;
- L, F, K and A, respectively;
- L, Y, R and A, respectively;
- L, Y, K and R, respectively;
- or L, Y, K and A, respectively,
- wherein 27th, 29th, 71st and 97th amino acid residues in SEQ ID NO:
- 10 are F, Y, K and A, respectively;
- L, F, K and A, respectively;
- L, Y, R and A, respectively;
- L, Y, K and R, respectively;
- or L, Y, K and A, respectively,
- wherein 27th, 29th, 71st and 97th amino acid residues in SEQ ID NO:
- 11 are F, Y, K and A, respectively;
- L, F, K and A, respectively;
- L, Y, R and A, respectively;
- L, Y, K and R, respectively;
- or L, Y, K and A, respectively, and
- wherein 37th and 47th amino acid residues in SEQ ID NO:
- 13 are V and W, respectively;
- or F and G, respectively.
Dependencies are inferred from the claim text.